All News

Rheumatoid,RA,nodules,damage

Complex Evolution of RA Management and Outcomes

Jack Cush, MD

FIRST is a Japanese longitudinal, real-world registry of rheumatoid arthritis (RA) management, and over the last 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain.

Read Article
pregnancy.sperm_.jpg

EULAR Guidelines on Reproductive Health

MedPage Today

Rheumatology patients considering or actually having babies can safely take most of the medications currently used to treat their conditions, according to an updated guideline from the European Alliance of Associations for Rheumatology (EULAR).

Read Article
FDA%20approved.jpg (keep)

FDA Approves Rinvoq for Giant Cell Arteritis

Jack Cush, MD

Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication for upadacitinib in the U.S. for use in rheumatology, gastroenterology, and dermatology.

Read Article
Lknee.OA_.jpg

Metformin Effective in Osteoarthritis

MedPage Today

The diabetes drug metformin provided overweight/obese patients with osteoarthritis (OA) of the knee with significantly greater pain relief than did placebo in a small randomized trial, researchers said.

Read Article
temperature.fever_.weather.jpg

2024 Management of Familial Mediterranean Fever Recommendations

Jack Cush, MD

A EULAR/PReS combined task force has developed recommendations for the management of Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease worldwide. These evidence-based recommendations update the 2016 recommendations developed for rheumatologists and other HCPs who care for FMF patients.

Read Article
RheumNow Podcast square

Rheumatology: Believe It or Not (4/25/2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?

Read Article
Norwegian RevNatus Pregnancy study on 417 births in 350 women w/ axSpA: 86% (347) were breastfeeding @6wks, 70% @6mos, & 38% @12 mos. Non-breastfeeders more likely to have C-section (41 vs 20%), higher ASDAS-CRP (2.6 vs 2.2), CRP (5.3 vs 3.3), & VAS pain (41 vs 32) https://t.co/DI6owL5dof
Dr. John Cush RheumNow ( View Tweet)
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not Sxs. https://t.co/Xsju7JdEVE
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?

Dr. John Cush RheumNow ( View Tweet)

Gout pts No-Shows after ED: Study of 159 gout pts w/ gout flare & ED visit - only 56 (35%) had an outpatient visit addressing gout within 6 mos. Higher odds w/ being married (OR 2.66), no comorbidities (OR 3.86), colchicine use (OR 2.7), being older (OR 1.44) https://t.co/tAorjwf8xX
Dr. John Cush RheumNow ( View Tweet)
Looking for the latest updates on treatments and disparities for patients with systemic lupus erythematosus and lupus nephritis? Join us at AWIR 2025 to learn from Maria Dall’Era, MD, Jean S. Engleman Distinguished Professor of Medicine and Chief of the Division of https://t.co/QPyojkztCj

Links:

Association of Women in Rheumatology AWIRGROUP ( View Tweet)
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?

Dr. John Cush RheumNow ( View Tweet)

Norwegian RevNatus Pregnancy study on 417 births in 350 women w/ axSpA: 86% (347) were breastfeeding @6wks, 70% @6mos, & 38% @12 mos. Non-breastfeeders more likely to have C-section (41 vs 20%), higher ASDAS-CRP (2.6 vs 2.2), CRP (5.3 vs 3.3), & VAS pain (41 vs 32) https://t.co/GhLtLqT0iS
Dr. John Cush RheumNow ( View Tweet)
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not https://t.co/VrLfiSGWGA
Dr. John Cush RheumNow ( View Tweet)
Simplistic overview of Lupus Nephritis - causes, risk factors, symptoms, diagnosis, and treatment of lupus nephritis. https://t.co/QkLXUQcSqo https://t.co/pGjCHmoelG

Links:

Dr. John Cush RheumNow ( View Tweet)
Better Responses with Chronotherapy for Baricitinib A nonrandomized, open-label, controlled trial has shown superior efficacy when baricitinib was given at night (instead of day); attesting to the benefits of chronotherapy - selective dosing meant to target the body's diurnal https://t.co/jSrPdoOpmo
Dr. John Cush RheumNow ( View Tweet)
Senescent "Zombie" Cells and Low Back Pain In a preclinical study led by McGill University researchers, two drugs targeting “zombie cells” have been shown to treat the underlying cause of chronic low back pain. The condition affects millions of people worldwide. https://t.co/UxHH3bMGkQ
Dr. John Cush RheumNow ( View Tweet)
Metanalysis suggests MTX may be effective in knee OA. 6RCTs, 602 pts of MTX vs PBO, showed MTX significantly relieved pain (mean diff −0.44; P 0.0003) knee/hand OA; Functional improved for knee only, but no differences in quality-of-life outcome or adverse events https://t.co/lmBEnTLFHY
Dr. John Cush RheumNow ( View Tweet)
Incr. neutrophils in RA synovium correlates w/ higher Dz activity and poorer Rx responses. Study of 55 #RA pts, 1/3 (17) enriched for synovial PMNs - these correlated w/ DAS28--CRP, synovial inflammation, and CD3+/CD68+ cell counts https://t.co/zz59w8MMUU https://t.co/R7Ruyab0wj

Links:

Dr. John Cush RheumNow ( View Tweet)
Hip replacement outcomes are not linked to OA severity, instead pts muscle quality before THA best predicts recovery after surgery. Imaging of 10 pts undergoing THA showed poor muscle quality predicted post-op performance/movement after surgery https://t.co/io0UXQl6n2 https://t.co/cFM7Fg10Zm

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×